Biosimilar switching maintains disease control in stable ankylosing spondylitis patients
Cheaper Arthritis Drugs Work Just as Well
This structured narrative review of patients with stable ankylosing spondylitis found that switching from reference biologics to biosimilars…
Switching to cheaper arthritis drugs keeps patients just as healthy while cutting treatment costs in half without losing results.
Sudden sensorineural hearing loss risk factors in ankylosing spondylitis patients on adalimumab plus methotrexate
Could long-term arthritis treatment raise your risk of sudden hearing loss?
This retrospective case-control analysis drew on 2,564 ankylosing spondylitis patients at Henan Provincial People's Hospital (2015-2024), co…
Patients with long-term ankylosing spondylitis taking adalimumab and methotrexate are more likely to experience sudden hearing loss than tho…
Phase III trial of AK111 for active ankylosing spondylitis completed with 510 patients
Can a new drug help people with painful spinal arthritis move more freely?
A Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluated AK111 in 510 patients with active ankylosing spondyli…
A new drug called AK111 aims to help people with painful spinal arthritis move more freely by improving symptoms like pain and stiffness.